DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Human Microbiome Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 - 2023" report to their offering.
Global Human Microbiome Market Estimated at CAGR of 21.1% During 2016-2023
The main driver of the global human Microbiome market is frequent use of probiotics, medical foods and prebiotics. Probiotics are those products which contains live bacteria and yeasts that are good for health, especially for digestive system. Generally bacteria are those living organisms that cause diseases. Body consists of bacteria, both good and bad. Probiotics are generally called "good" or "helpful" bacteria because they help to keep body healthy. Probiotics are naturally found in the body.
Some foods and supplements contains probiotic bacteria which on consumption gives benefits to the body such as Bifidobacterium is beneficial in treatment of infant diarrhea Continuous consumption of antibiotics can increase demand of efficient and safe medication but sometime it give rise to reaction also if it doesn't suits the person.
Additionally, changes in lifestyle led to increase in number of diseases, rise in population is another factor contributing to the increase of the diseases and is one of the major driver for the global microbiome market. Cancer and diabetics are some major disease increasing day by day In the Asia pacific region there are approximately 300,000 new cases of cancer and diabetics, which is more than half of the total cases globally. China and India are key emerging nation across the globe. China has biggest influence on Asia Pacific region growth. It is estimated that there were 4.3 million new cancer cases found, which around 2.8 million in 2015 were.
Some of the major players of the human Microbiome market are Vedanta Biosciences, Ritter pharmaceuticals, Actoginics, avidbiotics, rebiotix, osel, , Miomics, E.I. du Pont de Nemours, Second Genome.
Market Determinants
Market Drivers
- Increased Adoption of Human Microbiome Therapy
- Focus On Early Disease Detection And Diagnosis
- Growing Technological Drug Development
- Use of High Validation Model
Market Restraints
- Lack of Technological Market Expertise
- Lack of Comprehensive Approach
- Barriers in Early Detection And Diagnosis
- Minimal Awareness Regarding the Beneficial Use
Market Opportunities
- Growing R&D Investment
- Investment On New Drugs
- Increasing Growth in Emerging Market
- High Global Opportunities
Market Challenges
- Barrier for New Technology to Enter Into Market
- Stringent Government Regulations
Companies Mentioned
- Actogenix
- Avidbiotics
- Enterologics
- Enterome Bioscience
- Metabiomics
- Metabogen
- Microbiome Therapeutics Llc
- Miomics
- Osel
- Rebiotix
- Ritter Pharmaceuticals
- Second Genome
- Symberix
- Symbiotix Biotherapics
- Vedanta
For more information about this report visit http://www.researchandmarkets.com/research/k39x96/global_human
